ClinicalTrials.gg
CompletedNCT04915014BIPASSUpdated Nov 16, 2026

Sleeve Gastrectomy With Transit Bipartition(SG+TB) Versus Roux-en-Y Gastric Bypass (RYGB) for Type 3 Obesity

An interventional study of sleeve gastrectomy with transit bipartition (SG +TB) and Roux-en-Y gastric bypass (RYGB) in Severe Obesity, sponsored by University Hospital, Lille. Completed at 8 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Obesity, Morbid with a site in France — 13 open to participants now, 15 under way, none of them phase 3. Obesity, Morbid · France.

Enrollment
8th of 42
320 · median 100
Started
2021
with 3 others
No phase
36 of 66
7 open now
Registered
52nd of 66
by date
Lead sponsor
2 of 66
University Hospital, Lille

Among the 66 studies in Obesity, Morbid with a site in France, this one is the 8th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2021, is one of 36 with no phase, and was the 52nd registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

13 of the 66 studies in Obesity, Morbid with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Obesity, Morbid with a site in France, or all of them as a file.
02

Study summary

Obesity is a major public health problem worldwide. Bariatric surgery has proved to be the most effective treatment of morbid obesity in terms of weight reduction and remission of co-morbid conditions during long-term follow-up. Sleeve Gastrectomy (SG) has become the most performed intervention either worldwide or in France, where SG represents more than 60% of bariatric interventions and 114,817 patients operated between 2013 and 2016.

Maximum Excess weight loss (%EWL) after SG is obtained at one-year post surgery. Then it has been largely reported in the literature that patients could present mild, moderate or important (notably in the super obese patients) weight regain associated with comorbidity relapse motivating redo surgery. Like in revisional surgery, operating super-obese patient (BMI ≥50 kg/m2) is a challenge. It has been shown that achieving significant weight loss was more difficult in patients with a BMI ≥ 50 compared to lower BMIs.

Read the detailed description

In these 2 populations of patients, more malabsorptive procedures like long limb One Anastomosis Gastric Bypass or Bilio-Pancreatic Diversion with Duodenal Switch could be more efficient but induce technical difficulties (high complication rate) and can be responsible for malnutrition (vitamin deficiencies, hypoalbuminemia…). That's why, in case of revisional surgery or for high BMI patients,laparoscopic Roux-en-Y gastric bypass (RYGBP) is still considered as the gold standard and is the most performed intervention. To obtain better weight loss safely,Santoro et al. promoted the sleeve gastrectomy with transit bipartition (SG+TB), a new intervention coupling a SG without interrupting pathway through the duodenum and preserving the pylorus and a long biliary limb RYGBP.

Hypothesis: Because there is no duodenal and jejunal exclusion, malnutrition is expected to be less frequent after SG+TB compared to BPD/DS. Its anastomosis on the antrum makes SG+TB easier to perform in super-obese patient than standard RYGB but more efficient in term of weight loss. Compared to BPD/DS or SADI which involves dissection of the duodenum and the confection of a duodenojejunostomy, SG+TB is also expected to be easier then safer.

03

Conditions studied

  • Severe Obesity

Keywords

  • Severe obesity
  • Type 2 diabetes
  • Metabolic syndrome
  • Surgery
  • Malnutrition
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who has benefited from a pluridisciplinary evaluation, with a favorable opinion for SG+TB or RYGB as a first intention procedure with ≥40 kg/m2 or BMI ≥ 35 kg/m2 associated with one co-morbidity which will be improved by surgery (according to HAS 2009 recommendation3) OR as a second intention procedure (revisional surgery) after failure of Sleeve gastrectomy (defined as insufficient weight loss at 18 months after surgery (EWL% \<50), or as weight regain (+ 20%)).
  • Patient who had benefited from an Upper GI Endoscopy with to look for Helicobacter Pylori (HP) and a HP eradication.
  • Patient who understands and accepts the need for a long-term follow-up
  • Patient who agrees to be included in the study and who signs the form
  • Patient affiliated to a healthcare insurance plan

Exclusion criteria

Exclusion Criteria:

  • History of previous bariatric surgery, other than a Sleeve Gastrectomy
  • Patient with current > 60 kg/m2
  • Presence of a severe and evolutive life threatening pathology, unrelated to obesity
  • History of Chronic inflammatory bowel disease
  • Type 1 Diabetes
  • Pregnancy or desire to be pregnant during the study
  • Nursing woman
  • Presence of Pylori Helicobacter resistant to medical treatment
  • Presence of a non-healed gastro-duodenal ulcer or diagnosed less than 2 months previously
  • Severe esophagitis (grade C of Los Angeles classification)
  • Hiatal hernia
  • Patients with unstable psychiatric disorder, under supervision or guardianship
  • Patient who does not understand French/ is unable to give consent
  • Patient not affiliated to a French or European healthcare insurance
  • Patient who has already been included in a trial which has a conflict of interests with the present study
  • Patient incarcerated
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)

    One arm benefiting from a laparoscopic sleeve gastrectomy with transit bipartition (SG +TB)

    Procedure: sleeve gastrectomy with transit bipartition (SG +TB)

  • Sham comparator
    laparoscopic Roux-en-Y gastric bypass (RYGB)

    One arm benefiting from a laparoscopic Roux-en-Y gastric bypass (RYGB)

    Procedure: Roux-en-Y gastric bypass (RYGB)

Interventions

  • Proceduresleeve gastrectomy with transit bipartition (SG +TB)

    In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.

  • ProcedureRoux-en-Y gastric bypass (RYGB)

    A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.

06

What researchers measure

Primary outcomes

  1. The Excess Weight Loss percentage (EWL%)

    The Excess Weight Loss percentage (EWL%) calculated with the following formula: ((weight at 2 years visit - initial weight (kg)) / (initial weight - ideal weight)) X 100 Ideal weight defined as the weight corresponding to a BMI = 25 kg/m2. Initial weight defined as preoperative weight at V1. All weights are expressed in kg

    Time frame: at 2 years after surgery

Secondary outcomes

  1. Change nutritional status assessment

    Nutritional profil : Hemoglobin (g/l), albumin (g/l), prealbumin (g/l)

    Time frame: from baseline (before surgery) to 24 months after surgery

  2. Change in liver status assessment

    Liver parameters ( ALT AST GGT Alkaline phosphatases, Total bilirubin, prothrombin time, urea, creatininemia concentration)

    Time frame: from baseline (before surgery) to 24 months after surgery

  3. Change in vitamins status assessment

    vitamins profil (vitamin A B1, B6 B9, B12, C , D and E concentration)

    Time frame: from baseline (before surgery) to 24 months after surgery

  4. Change in mineral status assessment

    Mineral profil ( ferritin, potassium, calcium,iron, transferrin, magnesium, selenium, zinc phophore concentration)

    Time frame: from baseline (before surgery) to 24 months after surgery

  5. 24-hour steatorrhea quantified at 6 months

    24-hour steatorrhea is assessed to evaluate denutrition, expressed in g of lipid/24hr

    Time frame: At 6 months

  6. Evolution of muscle mass assessed by bioelectrical impedance analysis

    muscle mass is assessed to evaluate denutrition.

    Time frame: from baseline to 24 months after surgery

  7. Evolution of muscle mass assessed by grip strength test.

    muscle mass is assessed to evaluate denutrition.

    Time frame: from baseline to 24 months after surgery

  8. Complications rate within 2 years according to Dindo-Clavien classification

    complications rate is assessed to evaluate safety of the procedure

    Time frame: within 2 years

  9. Length of hospital stay defined as the number of days of hospitalization

    length of hospital stay for the surgical procedure

    Time frame: up to 2 week

  10. Evolution from baseline to 24 months after surgery of HbA1c level, HDL, LDL and triglycerides

    Evolution from baseline to 24 months after surgery of HbA1c level (expressed in %), fasting glycemia (expressed in mmol/l or g/l), HDL (expressed in mmol/l or g/l), LDL (expressed in mmol/l or g/l) and triglycerides (expressed in mmol/l)

    Time frame: from baseline to 24 months after surgery

  11. Evolution from baseline to 24 months of insulinoresistance defined by HOMA-IR calculated with fasting blood glucose and fasting insulinemia12

    assessment of insulinoresistance

    Time frame: from baseline to 24 months

  12. Change of the GIQLI score

    This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to patients and for each answer, a score is assigned, ranging from 0 to 4 (highest score = 144). A high score defines a more favorable health state

    Time frame: from baseline to 24 months after surgery

  13. Change of the SF36 scores

    This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health.

    Time frame: from baseline to 24 months after surgery

  14. Change in Sigstad questionnaire score (dumping syndrome).

    The Sigstad questionnaire allows the identification and diagnosis of postoperative hypoglycemia: a score \> 7 suggests a dumping and a score \<4 suggests another diagnosis. Complementary questions regarding timing of dumping (\<30 min or \>1h30) will be asked if Sigstad score \>7.

    Time frame: from baseline to 24 months after surgery

  15. Change of food choices and preferences assessed by the Leeds Food Preference Questionnaire (LFPQ) score.

    The Leeds Food Preference Questionnaire provides measures of different components of food preference and food reward. Participants are presented with an array of pictures of individual food items common in the diet. Foods in the array are chosen by the experimenter from a validated database to be either predominantly high (\>50% energy) or low (\<20% energy) in fat but similar in familiarity, protein content, sweet or non-sweet taste and palatability. Outcome measured are explicit Liking, explicit wanting, implicit wanting and food choice. Scores for explicit liking and explicit wanting range from 0-100 with a typical mean (±S.D.) of 60±18 Scores for Food Choice range from 0-48 and have a typical mean of 24±10 or for the appeal bias range from -48-48 with a typical mean of -5±15. Scores for Implicit Wanting typically range from -100-100 (due to RT there is no fixed min-max value) and have a typical mean of ±10±25 or for the appeal bias a typical mean of -10±30.

    Time frame: from baseline to 24 months after surgery

  16. Change of physical activity assessed by the International Physical Activity Index (IPAQ) score.

    The International Physical Activity Questionnaire assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives to estimate total physical activity in MET-min/week and time spent sitting.

    Time frame: from baseline to 24 months after surgery

07

Study locations

8 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in May 2026, 57 months.

Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 57 months is above that.

Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jul 2026 → May 2026 and completion Jul 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
Jun 7, 2021
StartActual
Jul 23, 2021
Primary completionActual
May 2, 2026was Jul 2026
CompletionActual
May 2, 2026was Jul 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 16, 2026
Primary completion
Jul 2026→May 2, 2026 (actual)
Nov 16, 2026
Study completion
Jul 2026→May 2, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Completed
    Primary completion Jul 2026→May 2, 2026 (now actual)
    Study completion Jul 2026→May 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04915014
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Jun 7, 2021
Start date
Jul 23, 2021
Primary completion
May 2, 2026
Completion
May 2, 2026
Last update
Nov 16, 2026

Study contacts

Robert CAIAZZO, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion